VTU Technology and the research company for the development of immortalized human primary-similar cells, Evercyte, develop together recombinant media additives (growth factors and cytokines) in order to satisfy the increasing demand for inexpensive cell culture additives with a consistently high quality.
As written in the producers' press release, they use the VTU own Pichia pastoris technology platform. Pichia pastoris (Komagataella pastoris) is a yeast which is biotechnologically used as an expression system for the production of pharmaceutical products. The fungus is considered as particularly safe because he has no disease-causing factors such as pyrogens and lysogenic viruses.
The constant product quality (biological activity and stability) is tested by Evercyte using accurate, repeatable, and relevant in-vitro test systems.
Further information:
http://www.vtu-technology.com/Evercyte-and-VTU-Technology-collaborate-on-development-of-recombinant-media-supplements-/en/2034
Literature:
J.L. Cereghino, J.M. Cregg (2000): Heterologous protein expression in the methylotrophic yeast Pichia pastoris. FEMS Microbiology Reviews 24: 45-66
-
font size
decrease font size
increase font size
Wednesday, 15 June 2016 11:57
Cooperation for a more cost-effective development of recombinant media Featured
Animal product-free, cell-specific media additives are not currently available for all cell types. The few industrially produced supplements are a cost factor for cell culture researchers. Therefore, two Austrian companies, VTU Technology and Evercyte, have started a cooperation.
Dr. rer. nat.
Menschen für Tierrechte - Tierversuchsgegner Rheinland-Pfalz e.V.